Stock Analysis

Navamedic Reports Full Year 2023 Earnings

OB:NAVA
Source: Shutterstock

Navamedic (OB:NAVA) Full Year 2023 Results

Key Financial Results

  • Revenue: kr512.0m (up 34% from FY 2022).
  • Net income: kr3.81m (down 87% from FY 2022).
  • Profit margin: 0.7% (down from 7.7% in FY 2022). The decrease in margin was driven by higher expenses.
earnings-and-revenue-growth
OB:NAVA Earnings and Revenue Growth February 17th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Navamedic Earnings Insights

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Norway.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 3 warning signs for Navamedic (1 is concerning!) that you need to be mindful of.

Valuation is complex, but we're here to simplify it.

Discover if Navamedic might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.